Development of sulfanegen for mass cyanide casualties

Steven Patterson, Bryant Moeller, Herbert T. Nagasawa, Robert Vince, Daune L. Crankshaw, Jacquie Briggs, Michael W. Stutelberg, Chakravarthy V. Vinnakota, Brian A. Logue

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Cyanide is a metabolic poison that inhibits the utilization of oxygen to form ATP. The consequences of acute cyanide exposure are severe; exposure results in loss of consciousness, cardiac and respiratory failure, hypoxic brain injury, and dose-dependent death within minutes to hours. In a mass-casualty scenario, such as an industrial accident or terrorist attack, currently available cyanide antidotes would leave many victims untreated in the short time available for successful administration of a medical countermeasure. This restricted therapeutic window reflects the rate-limiting step of intravenous administration, which requires both time and trained medical personnel. Therefore, there is a need for rapidly acting antidotes that can be quickly administered to large numbers of people. To meet this need, our laboratory is developing sulfanegen, a potential antidote for cyanide poisoning with a novel mechanism based on 3-mercaptopyruvate sulfurtransferase (3-MST) for the detoxification of cyanide. Additionally, sulfanegen can be rapidly administered by intramuscular injection and has shown efficacy in many species of animal models. This article summarizes the journey from concept to clinical leads for this promising cyanide antidote.

Original languageEnglish (US)
Pages (from-to)202-209
Number of pages8
JournalAnnals of the New York Academy of Sciences
Issue number1
StatePublished - 2016

Bibliographical note

Publisher Copyright:
© 2016 New York Academy of Sciences.


  • 3-MST
  • 3-mercaptopyruvate sulfurtransferase
  • cyanide antidote
  • cyanide poisoning
  • sulfanegen


Dive into the research topics of 'Development of sulfanegen for mass cyanide casualties'. Together they form a unique fingerprint.

Cite this